These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7933608)

  • 1. [Application of immunosuppressants for therapy of patients with vasculitis].
    Abe C
    Nihon Rinsho; 1994 Aug; 52(8):2177-81. PubMed ID: 7933608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
    N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Steroid and non-steroidal anti-inflammatory drug therapy of vasculitis].
    Abe T
    Nihon Rinsho; 1994 Aug; 52(8):2173-6. PubMed ID: 7933607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
    N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New strategies in diagnosis and therapy of vasculitides].
    Stierle HE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():143-6. PubMed ID: 16802540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necrotizing vasculitis--a 2009 update.
    Sharaf PH; Yazici Y
    Bull NYU Hosp Jt Dis; 2009; 67(3):303-5. PubMed ID: 19852754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic vasculitis: still a challenging disease.
    Buhaescu I; Covic A; Levy J
    Am J Kidney Dis; 2005 Aug; 46(2):173-85. PubMed ID: 16112036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How long should cyclophosphamide therapy of Wegener's granulomatosis continue?].
    Reinhold-Keller E
    Dtsch Med Wochenschr; 2002 Sep; 127(37):1909-10. PubMed ID: 12226791
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
    Kötter I
    Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of systemic vasculitides].
    Guillevin L; Pagnoux C
    Rev Prat; 2008 Mar; 58(5):541-4. PubMed ID: 18524111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CARI guidelines. Induction and maintenance therapy in ANCA-associated systemic vasculitis.
    Menahem S; Hiremagalur B; Mudge D; Toussaint N; Walters G;
    Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S24-36. PubMed ID: 18713121
    [No Abstract]   [Full Text] [Related]  

  • 16. Review article: Progress of treatment in ANCA-associated vasculitis.
    Jayne D
    Nephrology (Carlton); 2009 Feb; 14(1):42-8. PubMed ID: 19335843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus.
    Neumann R; Foster CS
    Retina; 1995; 15(3):201-12. PubMed ID: 7569347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The therapy of vasculitis].
    Andrassy K; Waldherr R; Hergesell O; Ritz E
    Dtsch Med Wochenschr; 1996 Aug; 121(31-32):985-7. PubMed ID: 8765402
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse effects of therapy for ANCA-associated vasculitis.
    Turnbull J; Harper L
    Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):391-401. PubMed ID: 19508946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.